The first healthy volunteer has received a small dose of a candidate vaccine developed by Imperial College London researchers. The volunteer, who has asked to remain anonymous, will be monitored closely and thus far is described as being “in good health, with no safety concerns.” A second dose will be delivered within four weeks. Nearly 300 other participants are expected to receive their first dose in the coming days. Previous studies have shown the potential vaccine to be safe in animals. Professor Robin Shattock from the Department of Infectious Disease at Imperial stated: “The first participant marks an important step for our saRNA vaccine platform, which has never before been trialled in humans.” Professor Shattock is leading the work as they assess the safety of the potential vaccine in humans, and determine correct dosage to ensure an immune response. If the vaccine proves safe and effective, larger trials could occur later this year.